IMMU
$15.66
Immunomedics
($.70)
(4.28%)
IMMU
Earnings Whisper ®
($0.47)
4th Quarter December 2019
Consensus:  ($0.44)
Revenue:  $0.00 Mil
Thursday
Feb 27
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when IMMU reports earnings?
Beat
Meet
Miss

Where is IMMU's stock price going from here?
Up
Flat
Down
Stock chart of IMMU
Analysts
Summary of analysts' recommendations for IMMU
Score
Grade
Pivots
Resistance
$17.88
$17.47
$16.91

$16.50

Support
$15.94
$15.53
$14.97
Tweet
Growth
Description
Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, the company have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. They have recently licensed its lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide.
Peers
Myriad GeneticsCareDxQuidelMeridian BioscienceSurModics